A new study published in Otolaryngology–Head and Neck Surgery reveals that glucagon-like peptide-1 receptor agonists ...
Please provide your email address to receive an email when new articles are posted on . The analysis compared results from the WAYPOINT, SINUS-52 and SYNAPSE studies. Tezepelumab outperformed ...
Biologic therapies may vary in their ability to improve olfactory function in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to a meta-analysis. Among the biologics analyzed, ...
Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...
THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the ...
Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the ...
Quirce had participated in advisory boards and received speaker fees from Allergy Therapeutics, AstraZeneca, Chiesi, GlaxoSmithKline, Gebro, Novartis, and Sanofi. Ceylan has no conflicts of interest ...
About The Study: Among patients with severe chronic rhinosinusitis with nasal polyps treated with a daily intranasal corticosteroid, stapokibart, a novel monoclonal antibody, reduced polyp size and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results